• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

AZ Deal Fuels Innate Pharma Share Surge


April 27, 2015.

Reuters reported Friday

that shares in French drug maker Innate Pharma surged to a record high - increasing by as much as 57 percent to €14 euros on volumes of 10.7 million shares - following its deal with AstraZeneca to accelerate and broaden development of its immune-boosting anti-cancer medicines.   Innate will receive an initial payment of $250 million from AstraZeneca, which is collaborating with Medimmune to develop the French firm's anti-NKG2A antibody, IPH2201 aimed at stimulating the body's immune system to destroy cancer cells. Reuters reports that "it is the most significant transaction ever by the Marseille-based biopharmaceutical company, worth about €700 million on the stock market even after Friday's share price jump".  


Related Videos